An in vitro tumor model: Analysis of angiogenic factor expression after chemotherapy

Cancer Research

Volumn 62, Issue 19, 2002, Pages 5597-5602

  Keyes, Kristan ^a   Cox, Karen ^a   Treadway, Patti ^a   Mann, Larry ^a   Shih, Chuan ^a   Faul, Margaret M ^a   Teicher, Beverly A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CARBOPLATIN; CYTOKINE; ENZASTAURIN; GEMCITABINE; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR CELL CULTURE;

3T3 CELLS; ANIMALS; CARBOPLATIN; CYTOKINES; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; NEOPLASMS; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036790090     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Connolly, J. L., Schnitt, S. J., Wang, H. H., Dvorak, A. M., and Dvorak, H. F. In: J. F. Holland, R. C. Bast, Jr., D. L. Morton, E. Frei III, D. W. Kufe, and R. R. Weichselbaum (eds.), Principles of Cancer Pathology. Cancer Medicine, Ed. 4, pp. 533-555. Philadelphia: Williams & Wilkins, 1997.
2. Cotran, R. S., Kumar, V., and Robbins, S. L. (eds.). Robbins Pathologic Basis of Disease, Ed. 5, pp. 272-280. Philadelphia: Saunders, 1994.
3. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med., 315: 1650-1659, 1986.
4. Dvorak, H. F., Nagy, J. A., and Dvorak, A. M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3: 77-85, 1991.
5. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
6. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med., 1: 27-33, 1995.
7. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Institute., 82: 4-6, 1989.
8. Teicher, B. A. (ed.) Antiangiogenic Agents in Cancer Therapy. Totowa, NJ: Humana Press, 1999.
9. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999.
10. Senger, D., Galli, S., Dvorak, A., Perruzzi, C., Harvey, V., and Dvorak, H. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Wash. DC), 219: 983-985, 1983.
11. Poon, R. T., Fan, S., and Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol., 19: 1207-1225, 2001.
12. Oliver, K. G., Kettman, J. R., and Fulton, R. J. Multiplexed analysis of human cytokines by use of the FlowMetrix system. Clin. Chem., 44: 2057-2060, 1998.
13. Vignali, D. A. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods, 243: 243-255, 2000.
14. Fulton, R. J., McDade, R. L., Smith, P. L., Kiener, L. J., and Kettman, J. R. Advanced multiplexed analysis with the FlowMetrix system. Clin. Chem., 43: 1749-1756, 1997.
15. Keij, J. F., and Steinkamp, J. A. Flow cytometric characterization and classification of multiple dual-color fluorescent microspheres using fluorescence lifetime. Cytometry, 33: 318-323, 1998.
16. Francis, J., Bernal, S. D., Gazdar, A. F., Thompson, R., and Baylin, S. L-Dopa decarboxylase activity (DCC): a distinguishing biomarker for the growth of small cell lung cancer (SCCL) in tissue culture. Proc. Am. Assoc. Cancer Res., 21: 52, 1980.
17. Teicher, B. A., Menon, K., Alvarez, E., Liu, P., Shih, C., and Faul, M. M. Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human hepatocellular and gastric cancer xenografts. In Vivo, 15: 185-194, 2001.
18. Hahn, G. M., and Little, J. B. Plateau phase cultures of mammalian cells: an in vitro model for human cancer. Curr. Top. Radiat. Res. Q., 8: 39-43, 1972.
19. Ray, G. R., Hahn, G. M., Bagshaw, M. A., and Kurkjian, S. Cell survival and repair of plateau phase cultures after chemotherapy: relevance to tumor therapy and to the in vitro screening of new agents. Cancer Chemother. Rep., 57: 473-475, 1973.
20. Weichselbaum, R. R. The role of DNA repair processes in the response of human tumors to fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 10: 1127-1134, 1982.
21. Wang, Y., Herman, T. S., and Teicher, B. A. Platinum-dye complexes inhibit repair of potentially lethal damage following bleomycin treatment. Br. J. Cancer, 59: 722-726, 1989.
22. Bhuyan, B. K., Scheidt, L. G., and Fraser, T. J. Cell cycle phase specificity of antitumor agents. Cancer Res., 32: 398-407, 1972.
23. Barranco, S. C., and Humphrey, R. M. The effects of 1, 3-bis(2-chloroethyl)-1-nitrosourea on survival and cell progression in Chinese hamster cells. Cancer Res., 31: 191-195, 1971.
24. Barranco, S. C., Kue, J. K., Romsdahl, M. M., and Humphrey, R. M. Bleomycin as a possible synchronizing agent for human tumor cells in vivo. Cancer Res., 33: 882-887, 1973.
25. Berg, W. J., Divigi, C. R., Nanus, D. M., and Motzer, R. J. Novel investigative approaches for advanced renal cell carcinoma. Semin. Oncol., 27: 234-239, 2000.
26. Amato, R. J. Chemotherapy for renal cell carcinoma. Semin. Oncol., 27: 177-186, 2000.
27. Motzer, R. J., and Russo, P. Systemic therapy for renal cell carcinoma. J. Urol., 163: 408-417, 2000.
28. Keyes, K. A., Mann, L., Cox, K., Treadway, P., Iversen, P., Chen, Y-F., and Teicher, B. A. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex multiplex technology. Cancer Chemother. Pharmacol., submitted, 2002.